



EUROPEAN COMMISSION  
JOINT RESEARCH CENTRE

Directorate F – Health and Food  
**Disease Prevention**

## **Annual Declaration of Interests<sup>1</sup> (DoI) form (v3)**

European Commission Initiative on Breast Cancer (ECIBC)

**Please answer each of the questions below.**

**If the answer to any of the questions is "Yes"<sup>2</sup>, please complete the corresponding fields, describing the circumstances, as appropriate.**

**If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the current ECIBC activities.**

**If you do not disclose relevant activities of interest for the ECIBC, your role may be revised.**

---

<sup>1</sup> According to European Commission's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 11 each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

<sup>2</sup> Answering "Yes" to the questions on this form does not automatically limit your participation in the ECIBC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (i.e. any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

<b>Name and Surname:</b>	<b>LIVIA GIORDANO</b>
--------------------------	-----------------------

Activities	Yes/No	Period (From - To)	Information	Details
<b>1. Do you have current investments<sup>3</sup> in a legal entity<sup>4</sup> with an interest related to breast cancer which either:</b> <ul style="list-style-type: none"> <li>• has a value of more than 10.000 EUR, or</li> <li>• entitle you to a voting right of 5% or more?</li> </ul>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please provide information about where the investment is placed (Name, Country, Public/Private).	[Please describe the entity and your role.]
<b>2. Have you, within the last five years (January 2018 – December 2022), received remuneration from a legal entity with an interest related to breast cancer?</b>  <b>A. Employment</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> <li>• Name, Place of the entity;</li> <li>• Type of the entity: public, private, etc.;</li> <li>• The received amounts for remunerated activities.</li> </ul>	[Please describe your role.]

<sup>3</sup> **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

<sup>4</sup> **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities	Yes/No	Period (From - To)	Information	Details
<b>B. Consultancy, including advisory activities</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> <li>• Name, Place of the entity;</li> <li>• Type of the entity: public, private, etc.;</li> </ul> The received amounts for remunerated activities.	Please describe your role.

<p><b>Have you, within the past five years (January 2018 – December 2022), been involved in research related to breast cancer?</b></p> <p><b>Have you been an investigator in research studies on breast cancer?</b></p> <p><b>For the mentioned research studies, did you receive support<sup>5</sup>?</b></p>	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	2015-2018	The Andromeda Study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers	<p>Principal investigator</p> <p>The Andromeda study aims to stratify the risk in order to maximise the impact of screening in high-risk women and the cost-benefit ratio; 2) to assess the predictive value, sensitivity and specificity of about 20 non-coding microRNAs and their association with women's characteristics (age, risk factors, lifestyle) of the tumour and the presence of 18 polymorphisms (SNPs) associated with breast cancer.</p>
		2015-2020	EU-TOPIA project: towards improved screening for breast, cervical and colorectal cancer in All of Europe	<p>Collaborator</p> <p>The EU-TOPIA project assessed and quantified harms and benefits of screening programmes for breast, cervical and colorectal cancer in all European countries, and identified approaches to improve their impact in terms of health and equity.</p>
		2016-2019	Euromed/Inca : recruitment strategies for breast and cervical cancer screening in 3 mediterranean countries (Albania, Montenegro, Morocco)	<p>Principal investigator</p> <p>The project evaluated the effectiveness of different recruitment strategies as well as main reasons for attending or refusing cervical screening in three low-and-middle income countries across the Mediterranean area: Albania, Montenegro and Morocco.</p>

---

<sup>5</sup> **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

		2017/2019	SMART project : Innovative strategies to improve healthy lifestyle habits and to reduce the incidence of cancer and other NCDs	Principal Investigator The overall objective of the project is to increase the prevalence of healthy behaviour in the population attending breast and cervical screening programmes in three Italian regions.
		2018-current	MyPebs project Multicentric Randomised Comparison of risk-stratified versus standard breast cancer screening in European women aged 40-70.	Workpackage coordinator MyPeBS (My Personal Breast Screening) compares a personalised screening strategy on the basis of risk (the individual risk each woman has of developing breast cancer) with regular screening of 85,000 women aged 40 to 70 years in six countries: Belgium, France, Israel, Italy, the United Kingdom and Spain.
		2018-current	EU leagues project	Collaborator Collaboration agreement with the Association of European Cancer Leagues (ECL) to carry out specialised technical support activities in support of ECL's long-term strategic goal 'Encouraging access to cancer screening
		2018-current	The MAITA project Tomosynthesis as a primary test for breast cancer screening: a multicenter randomized controlled trial	Principal local investigator The project aims to investigate the validity of using Digital Breast Tomosynthesis (DBT) as a promising tool for breast cancer screening.

		2020-current	The MISS project : What is the best interval to screen women 45-49 and 70-74 for breast cancer?	Local principal investigator MISS project includes: a) a randomised controlled, prospective study to determine the optimal screening interval for women aged 45-49 years, with and without high mammography density; b) a retrospective observational study, with the same aim, on women aged 70-74 years; c) a qualitative research to understand how a possible extension of the screening interval might be perceived and to identify the best ways to communicate these changes to the population, especially when the new intervention is less frequent than the existing one.
		2021-current	The EU TOPIA EAST project : TOwards imProved screening for breast, cervical and colorectal cancer in Eastern-Europe: Equitable, Actionable, Sustainable and Trustworthy	Collaborator The overall goal of EU-TOPIA-EAST is to implement effective screening programmes for breast, cervical and colorectal cancer in three exemplary MICs in Eastern Europe (Georgia, Romania and Montenegro) and to build capacity for screening implementation in other Eastern European and Mediterranean countries, in order to reduce the cancer burden in these countries and to achieve equity in cancer care.

Activities	Yes/No	Period (From - To)	Information	Details
		2022-current	EU_CanScreen-ECIS: Strengthening cancer screening data collection to update European Cancer Information System and improve quality and coverage of cancer screening programmes in Europe	Collaborator ECIS aims to support research as well as public-health decision-making in the field of cancer and to serve as a point of reference and information for European citizens.
		2022-current	Boosting the usability of the EU Mobile App for Cancer Prevention (BUMPER)	Workpackage coordinator This proposal aims to increase the European Code against Cancer knowledge in the general population through the use of an 'EU Mobile App for Cancer Prevention'.
		2022 – current	ThermoBreast – Non-contact Breast Cancer Imaging using AI-enhanced Thermography	Collaborator The study will be essential to develop a novel risk-free and cost-effective breast imaging modality facilitating screening of women of all age groups and breast densities, enabling early detection of abnormalities caused by malignant processes and better patient monitoring.



	Yes <input checked="" type="checkbox"/>	2015-2018	The Andromeda Study : 250 000,00 Euros -AIRC (Associazione Italiana per la Ricerca sul Cancro) Type : private onlus	The Andromeda Study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers
	No <input type="checkbox"/>	2015-2020	EU-TOPIA project: 309 025,00 Euros European Commission	EU-TOPIA project: towards imProved screening for breast, cervical and colorectal cancer In All of Europe
		2016-2019	Euromed/Inca: 150 000,00 Euros Institut national du Cancer (Paris) Type. Public	Euromed/Inca : recruitment startegies for breast and cervical cancer screening in 3 mediterranean countries (Albania, Montenegro, morocco)
		2017-2019	SMART project: 439 800,00 Euros Italian Ministry of Health Type. Public	SMART project : Innovative strategies to improve healthy lifestyle habits and to reduce the incidence of cancer and other NCDs
		2018-current	MyPebs project : 593.399,92 Euros European Commission Type. Public	MyPebs project Multicentric Randomised Comparison of risk-stratified versus standard breast cancer screening in European women aged 40-70.
		2018-current	The MAITA project : 115 700, 00 Euros Italian Ministry of Health Type : public	The MAITA project Tomosynthesis as a primary test for breast cancer screening: a multicenter randomized controlled trial

		2018-current	EU Leagues project : 45 000,00 Euros ECL (European Cancer Leagues) Type. Private onlus	
		2020-current	The MISS project : 80 500,00 Euros Italian Ministry of Health Type. Public	The MISS project : What is the best interval to screen women 45-49 and 70-74 for breast cancer?
		2021-current	The EU TOPIA EAST project : 299 120,00 European Commission Type : public	The EU TOPIA EAST project : TOwards imProved screening for breast, cervical and colorectal cancer in Eastern-Europe: Equitable, Actionable, Sustainable and Trustworthy
		2022-current	EU_CanScreen-ECIS: 321.000,00 Euros European Commission	EU_CanScreen-ECIS: Strengthening cancer screening data collection to update European Cancer Information System and improve quality and coverage of cancer screening programmes in Europe.
		2022-current	BUMPER : 161 675.28 Euros European Commission	Boosting the usability of the EU Mobile App for Cancer Prevention
		2022-current	ThermoBreast : 470.000,00 Euros European Commission	Non-contact Breast Cancer Imaging using AI-enhanced Thermography

Activities	Yes/No	Period (From - To)	Information	Details

<b>3. Do you have a membership in national or international organisations<sup>6</sup>, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies with an interest in breast cancer?</b>	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	1994-current	Gruppo Italiano Screening Mammografico (Gisma)- Italian Group for mammographic screening - Italy - Nature: non profit organisation	Function of body: The Gisma group is a scientific Association with the aim to support and monitor the breast cancer screening activities in Italy. Function of expert: Epidemiologist – participating in a decision making process about the adolopment of the European breast cancer screening guidelines Link to website of body: <a href="http://www.gisma.it">www.gisma.it</a>
		2012-current	Europa Donna - Italy	Function of body: The Italian group of Europa Donna has the aim to facilitate the exchange and spread of pertinent information concerning breast cancer and to promote breast awareness among Italian women Function of expert: Member – participating in several decision making processes about the role of ED in breast cancer screening; Link to website of body: <a href="http://www.europadonna.it">www.europadonna.it</a>
		2014 – current	Responsible for the WHO Collaborating Centre for screening and cancer prevention	Support WHO in reinforcing cancer screening strategies as a health problem and in the development, review and dissemination of tools for effective screening in cancer Function of body: Multidisciplinary approach to breast cancer Function of expert: epidemiologist

Activities	Yes/No	Period (From - To)	Information	Details
		2016-current	Centro di Senologia della Svizzera Italiana (CSSI) - Lugano Switzerland	Link to website of body: <a href="http://www.eoc.ch">http://www.eoc.ch</a>
		2022-current	ESGO Prevention Committee	ESGO is the European Society of Gynaecological Oncology, a growing not-for profit organisation and forum of more than 3,400 professionals from across Europe and all around the world, dedicated to promoting the highest quality of care for women with gynaecological cancers
<b>4. Did you take part in other activities with interests related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	Please describe the activity.
<b>5. Do you have intellectual property rights (IPR)<sup>7</sup> related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	Please describe the IPR.

<sup>6</sup> **Organisation** refers to a governmental, international or non-profit organisation.

<sup>7</sup> **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities	Yes/No	Period (From - To)	Information	Details
<b>6. Do any of your immediate family members<sup>8</sup> have direct interests related to breast cancer that could undermine your independence?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	Please describe the interest.

---

<sup>8</sup> **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

**Notes:**

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>9</sup> before you send the DoI form to the Joint Research Centre (JRC), European Commission.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending a message as soon as possible to: [JRC-CANCER-POLICY-SUPPORT@ec.europa.eu](mailto:JRC-CANCER-POLICY-SUPPORT@ec.europa.eu).

- I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the European Commission Initiative on Breast Cancer membership<sup>10</sup>.
- I am informed that my personal data are stored, processed and published by the European Commission in accordance with Regulation (EU) 2018/1725<sup>11</sup>.

**Name and Surname: Livia Giordano**

**Date: 9/5/23**

**Signature:**



**Place: Turin**

---

<sup>9</sup> Personal data processing including the Declaration of Interests

<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

<sup>10</sup> Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

<sup>11</sup> Protection of individuals with regard to the processing of personal data

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>